US Patent 7625739 None
Patent 7625739 was granted and assigned to Intralytix on December, 2009 by the United States Patent and Trademark Office.
All edits
Edits on 17 Sep, 2023
Golden AI
Edits made to:
Infobox (+2 properties)
Infobox
Patent Inventor Names
Alexander Sulakvelidze0
Gary R. Pasternack0
Edits on 16 Sep, 2023
Golden AI
Edits made to:
Article (+307 characters)
Article
Patent abstract
The present invention is directed to isolated bacteriophage having strong lytic activity against strains of Clostridium perfringens, and methods of using that bacteriophage, and/or progeny or derivatives derived therefrom, to control the growth of Clostridium perfringens in various settings.
Edits on 19 May, 2023
Golden AI
Edits made to:
Infobox (+1/-1 properties)
US Patent 07625739 None US Patent 7625739 None
Infobox
Patent Number
07625739
Patent Number
7625739
Edits on 18 May, 2023
Golden AI
Edits made to:
Infobox (-1 properties)
Infobox
Official Website
Edits on 18 Jun, 2022
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Website URL
Edits on 3 Dec, 2021
Golden AI
Edits made to:
Infobox (+8 properties)
US Patent 07625739 None
Infobox
Is a
Current assignee
Patent jurisdiction
Patent number
07625739
Date of patent
December 1, 2009
Patent application number
11838625
Date Filed
August 14, 2007
Patent primary examiner
Find more entities like US Patent 7625739 None
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
By using this site, you agree to our Terms of Service.